The new CEO of JSR, Tetsuro Hori, aims to prioritize improving the company's financial performance over pursuing industry consolidation plans. The focus will be on reviving the struggling life science business, acknowledging the need for recovery before considering any potential sale. JSR's recent financial challenges, including losses in its life sciences unit, have raised speculation about the division's future ownership. Hori emphasized the importance of enhancing business performance before making any decisions. Previously, JSR was taken private in a deal with Japan Investment Corp, led by outgoing CEO Eric Johnson. Hori stressed that any future mergers or acquisitions should be customer-driven and offer tangible value. Despite his recent appointment as CEO, Hori is already committed to steering JSR toward profitability by the end of the next financial year.